- Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.2009 | First Faculty of Medicine
- Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy2009 | First Faculty of Medicine
- Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data2015 | First Faculty of Medicine
- Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy2009 | Publication without faculty affiliation
- The use of 5-FU pharmacogenomics from paraffin blocks in patients with breast cancer receiving fluorouracil therapy2015 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis2014 | First Faculty of Medicine
- Molecular profile of 5-fluorouracil pathway genes in colorectal carcinoma2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients2018 | First Faculty of Medicine, Faculty of Medicine in Pilsen